8 research outputs found
Sustainability, natural and organic cosmetics: consumer, products, efficacy, toxicological and regulatory considerations
Skin Penetration of Epigallocatechin-3-Gallate and Quercetin from Green Tea and Ginkgo biloba Extracts Vehiculated in Cosmetic Formulations
Green tea (Camellia sinensis) and Ginkgo biloba extracts in cosmetic formulations have been suggested to protect the skin against UV-induced damage and skin ageing. Thus, it is very important to assess the human skin penetration of their major flavonoids to verify if they penetrate and remain in the skin to exert their proposed effects. The aim of this study was to evaluate the human skin penetration of epigallocatechin-3-gallate (EGCG) and quercetin from green tea and G. biloba extracts vehiculated in cosmetic formulations. This study was conducted with fresh dermatomed human Caucasian skin from abdominal surgery mounted on static Franz diffusion cells. Skin samples were mounted between two diffusion half-cells and 10 mg/cm(2) of formulations supplemented with 6% of green tea or G. biloba extract were applied on the skin surface. The receptor fluid was removed after 6 and 24 h and analyzed by high-performance liquid chromatography for the quantification of the flavonoids. The stratum corneum was removed by tape stripping and immersed in methanol and the epidermis was mechanically separated from the dermis and triturated in methanol to extract EGCG and quercetin. The results showed that the flavonoids under study penetrated into the skin, without reaching the receptor fluid. The majority of EGCG was quantified in the stratum corneum (0.87 mu g/cm(2)), which was statistically higher than the EGCG concentrations found in viable epidermis (0.54 mu g/cm(2)) and in the dermis (0.38 mu g/cm(2)). The majority of quercetin was quantified in the viable epidermis (0.23 mu g/cm(2)), which was statistically higher than the EGCG concentration found in the stratum corneum layer (0.17 mu g/cm(2)). Finally, it can be concluded that EGCG and quercetin from green tea and G. biloba extracts vehiculated in cosmetic formulations presented good skin penetration and retention, which can favor their skin effects. Copyright (C) 2009 S. Karger AG, BaselConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazi
Beneficial Effect Of Crotamine In The Treatment Of Myasthenic Rats
Introduction: Crotamine is a basic, low-molecular-weight peptide that, at low concentrations, improves neurotransmission in isolated neuromuscular preparations by modulating sodium channels. In this study, we compared the effects of crotamine and neostigmine on neuromuscular transmission in myasthenic rats. Methods: We used a conventional electromyographic technique in in-situ neuromuscular preparations and a 4-week treadmill program. Results: During the in-situ electromyographic recording, neostigmine (17 μg/kg) caused short-term facilitation, whereas crotamine induced progressive and sustained twitch-tension enhancement during 140 min of recording (50 ± 5%, P < 0.05). On the treadmill evaluation, rats showed significant improvement in exercise tolerance, characterized by a decrease in the number of fatigue episodes after 2 weeks of a single-dose treatment with crotamine. Conclusions: These results indicate that crotamine is more efficient than neostigmine for enhancing muscular performance in myasthenic rats, possibly by improving the safety factor of neuromuscular transmission. © 2012 Wiley Periodicals, Inc.474591593Dierdorf, S.F., Walton, S., Anesthesia for patients with rare and coexisting diseases (2006) Clinic anesthesia, p. 502. , Barash PG, Cullen BF, Soelting RK, editors., 5th ed. Philadelphia: Lippincott Williams and WilkinsArgov, Z., Management of myasthenic conditions: nonimmune issues (2009) Curr Opin Neurol, 22, pp. 493-497Qian-Sheng, Y., Harold, W.H., Weiming, L., Debomoy, K.L., Arnold, B., Nigel, H., Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine (2010) Bioorg Med Chem, 18, pp. 4687-4693Barrio, A., Vital Brazil, O., Neuromuscular action of the Crotalus terrificus terrificus poisons (1951) Acta Physiol Latinoam, 1, pp. 291-308Gonçalves, J.M., Polson, A., The electrophoretic analysis of snake venoms (1947) Arch Biochem, 13, pp. 253-259Gonçalves, J.M., Estudos sobre venenos de serpentes brasileiras. II-Crotalus terrificus crotaminicus, subespécie biológica (1956) Ann Acad Bras Ci{ring in equal to}nc, 28, pp. 365-367Rádis-Baptista, G., Kerkis, I., Crotamine, a small basic polypeptide myotoxin from rattlesnake venom with cell-penetrating properties (2011) Curr Pharm Des, 17, pp. 4351-4361Ownby, C.L., Structure, function and biophysical aspects of the myotoxins from snake venoms (1998) J Toxicol Toxin Rev, 17, pp. 213-238Vital Brazil, O., Prado-Franceschi, J., Laure, C.J., Repetitive muscle responses induced by crotamine (1979) Toxicon, 17, pp. 61-69Matavel, A.C.S., Ferreira-Alves, D.L., Beirão, P.S.L., Cruz, J.S., Tension generation and increase of voltage-activated sodium current by crotamine (1998) Eur J Pharmacol, 348, pp. 167-173Vital Brazil, O., Fontana, M.D., Toxins as tools in the study of sodium channel distribution in the muscle fiber membrane (1993) Toxicon, 31, pp. 1085-1098Chang, C.C., Tseng, K.H., Effect of crotamine, a toxin of South American rattlesnake venom, on the sodium channel of murine skeletal muscle (1978) Br J Pharmacol, 63, pp. 551-559Camillo, M.A.P., Arruda Paes, P.C., Troncone, L.R.P., Rogero, J.R., Gyroxin fails to modify in vitro release of labeled dopamine and acetylcholine from rat and mouse striatal tissue (2001) Toxicon, 39, pp. 843-853Kawanami, S., Mori, S., Experimental autoimmune myasthenia gravis induced by thymic acetylcholine receptor-like protein (1994) Fukuoka Igaku Zasshi, 85, pp. 120-127Dal Belo, C.A., Leite, G.B., Fontana, M.D., Corrado, A.P., Zanandréa Baso, A.C., New evidence for a presynaptic action of prednisolone at neuromuscular junction (2002) Muscle Nerve, 26, pp. 37-43Brown, G.L., The neuromuscular junction (1938) J Physiol, 92, p. 22Priviero, F., De Nucci, G., Antunes, E., Zanesco, A., Negative chronotropic response to adenosine receptor stimulation in rat right atria after run training (2004) Clin Exp Pharmacol Physiol, 31, pp. 741-743Pourmand, R., Myasthenia gravis (1997) Dis Mon, 43, pp. 65-109Tzartos, S.J., Barkas, T., Cung, M.T., Mamalaki, A., Marraud, M., Orlewski, F., Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor (1998) Immunol Rev, 163, pp. 89-120Serra, A., Ruff, R., Kaminski, H., Leigh, J.R., Factors contributing to failure of neuromuscular transmission in myasthenia gravis and the special case of the extraocular muscles (2011) Ann NY Acad Sci, 1233, pp. 26-33Pritchard, E.A.B., The use of "Prostigmin" in the treatment of myasthenia gravis (1935) Lancet, 1, pp. 432-434Sieb, J.P., Myasthenia gravis: emerging new therapy options (2005) Curr Opin Pharmacol, 5, pp. 303-307Mehndiratta, M.M., Pandey, S., Kuntzer, T., Acetylcholinesterase inhibitor treatment for myasthenia gravis (2011) Cochrane Database Syst Rev, 16, pp. CD006986Mantegazza, R., Bonanno, S., Camera, G., Antozzi, C., Current and emerging therapies for the treatment of myasthenia gravis (2011) Neuropsychiatr Dis Treat, 7, pp. 151-160Richman, D.P., Agius, M.A., Treatment of autoimmune myasthenia gravis (2003) Neurology, 61, pp. 1652-1661Toyama, M.H., Marangoni, S., Novello, J.C., Leite, G.B., Prado-Franceschi, J., da Cruz-Höfling, M.A., Biophysical, histopathological and pharmacological characterization of crotamine isoforms F22 and F32 (2003) Toxicon, 41, pp. 493-500Ponce-Soto, L.A., Martins-de-Souza, D., Novello, J.C., Marangoni, S., Structural and biological characterization of two crotamine isoforms IV-2 and IV-3 isolated from the Crotalus durissus cumanensis venom (2007) Protein J, 26, pp. 533-540Ponce-Soto, L.A., Martins-de-Souza, D., Marangoni, S., Structural and pharmacological characterization of the crotamine isoforms III-4 (MYX4-CROCu) and III-7 (MYX7-CROCu) isolated from the Crotalus durissus cumanensis venom (2010) Toxicon, 55, pp. 1443-1452Slater, C.R., Structural factors influencing the efficacy of neuromuscular transmission (2008) Ann NY Acad Sci, 1132, pp. 1-1